Navigation Links
Portola Pharmaceuticals Announces Positive Data from a Phase II,Study of its Factor Xa Inhibitor at the XXI Congress of the,International Society on Thrombosis and Haemostasis

ere adjudicated by a blinded, independent central adjudication committee. The study was not powered to show a dose response with PRT054021 or efficacy of PRT054021 versus enoxaparin.

About PRT054021 -- Portola's Factor Xa Inhibitor

PRT054021 is an oral Factor Xa inhibitor, an anticoagulant initially being studied for the prevention of venous thromboembolism in patients who have undergone orthopedic surgery. Portola expects to develop PRT054021 for additional indications including stroke prevention in patients with atrial fibrillation and secondary prevention of myocardial infarction and stroke. Factor Xa is a validated target (one for which there are approved drugs on the market), and inhibiting its activity is believed to have superior anticoagulant properties compared to other targets such as thrombin. Portola believes its oral Factor Xa inhibitor will offer several advantages, including a twenty hour pharmacodynamic half-life to support once daily dosing and a low peak-to-trough concentration ratio, resulting in consistent activity that does not require monitoring or dose adjustment. In addition, PRT054021 is not excreted in the kidneys and therefore will not require dose adjustment in patients with impaired renal function. PRT054021 is expected to enter Phase III clinical development in the first half of 2008.

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals, Inc. is a privately-held biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapeutics for acute and chronic cardiovascular and vascular disease. Portola is currently developing two clinical stage antithrombotics. Portola's lead compound, PRT054021, is an oral Factor Xa inhibitor for the prevention of venous thromboembolism after orthopedic surgery, for stroke prevention in patients with atrial fibrillation and for secondary prevention of myocardial infarction (MI) and stroke. Portola's second compound, PRT060128, is an o
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Portola Pharmaceuticals Announces Positive Phase II Results for PRT054021 for Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery
3. Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP Receptor Antagonist at the American College of Cardiology
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:10/8/2008)... LYON, France, Oct. 8 /- Vical Inc...anded clinical data and new nonclinical data,demon...may be broadly,applicable in DNA- and protein-base...ncer vaccines. Alain P. Rolland, Pharm.D., Ph.D., ...nt, will present the data today,Wednesday, Octobe...
(Date:10/7/2008)... SAN DIEGO, Oct. 7 /- Prometheus L...ny, today announced findings from its,development ...y blood test,for irritable bowel syndrome (IBS). T...expression of particular biomarkers in blood sampl...ation of these biomarkers,combined with a proprie...
(Date:10/7/2008)...Study evaluates the efficacy of new device for det...ssed during colonoscopy, ORLANDO, Fla., Oct. 7 /P...erology Annual Scientific Meeting in Orlando (ACG ... MD presented results from a,multi-institutional c...hird,Eye(R) Retroscope(R), a new device that is de...
(Date:10/7/2008)... Results of FLEXX Trial Presented at the Osteoa...ld Congress, PARSIPPANY, N.J., Oct. 7 /PRNewswire...ed results from the FLEXX Trial of Osteoarthritis ...yaluronate), a highly pure,non-avian high molecula...IA-HA), is superior to intra-articular saline (IA-...
Breaking Medicine Technology:Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 2Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 3National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 2National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 3National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 4National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 5Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 2Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 3Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 4Continua Health Alliance Provides Insight Into Next Generation of Digital Health at CONNECTIONS 28TM 29 20074 1Continua Health Alliance Provides Insight Into Next Generation of Digital Health at CONNECTIONS 28TM 29 20074 2North Castle Partners Names Dennis Lee of Octane Fitness CEO of the Year 20071 1North Castle Partners Names Dennis Lee of Octane Fitness CEO of the Year 20071 2North Castle Partners Names Dennis Lee of Octane Fitness CEO of the Year 20071 3Key to Angelina Like Cheeks 3F Add Volume to Deep Fat Compartment 20068 1Key to Angelina Like Cheeks 3F Add Volume to Deep Fat Compartment 20068 2Advanced Life Sciences Selected as Founding Member of the New NASDAQ OMX AeA Illinois Tech Index 5589 1Advanced Life Sciences Selected as Founding Member of the New NASDAQ OMX AeA Illinois Tech Index 5589 2Advanced Life Sciences Selected as Founding Member of the New NASDAQ OMX AeA Illinois Tech Index 5589 3Advanced Life Sciences Selected as Founding Member of the New NASDAQ OMX AeA Illinois Tech Index 5589 4
...linical study of,HGS-ETR1 -, ROCKVILLE, Md., April...ciences, Inc. today reported that clinical and pre...g that its TRAIL receptor,antibodies, HGS-ETR1 (ma...icant potential for use in the treatment of a broa...d HGS-ETR2 could offer novel, highly,targeted ther...
...llaGenex,Pharmaceuticals, Inc. (NASDAQ:CGPI) today... of the Journal of the American Academy,of Dermato...trials,demonstrated the efficacy and safety of an... doxycycline, USP capsules) for the,treatment of r...tablish the first important body of evidence suppo...
Other Medicine Technology:Human Genome Sciences Reports Growing Evidence That Its TRAIL,Receptor Antibodies Have Significant Potential in the Treatment of,a Broad Range of Cancers 2Human Genome Sciences Reports Growing Evidence That Its TRAIL,Receptor Antibodies Have Significant Potential in the Treatment of,a Broad Range of Cancers 3Human Genome Sciences Reports Growing Evidence That Its TRAIL,Receptor Antibodies Have Significant Potential in the Treatment of,a Broad Range of Cancers 4Human Genome Sciences Reports Growing Evidence That Its TRAIL,Receptor Antibodies Have Significant Potential in the Treatment of,a Broad Range of Cancers 5Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory,Dose Doxycycline for the Treatment of Rosacea 2Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory,Dose Doxycycline for the Treatment of Rosacea 3Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory,Dose Doxycycline for the Treatment of Rosacea 4
(Date:10/10/2008)...e testing is often on those already on drugs, some..., FRIDAY, Oct. 10 (HealthDay News) -- A new study ... Clostridium difficile ( C. difficile ) infections...rchers with McGill University and the Jewish Gener...senior citizens who acquired C. difficile infect...
(Date:10/10/2008)...MONTVALE, N.J., Oct. 10 /PRNewswire-FirstCall/ -- ...s that it has appointed William,(Bill) Federici, 4...to five,members., Mr. Federici joined West Pharma...ncial Officer in August of 2003. Under his financi... grown to more than $1.0 billion from,$300 million...
(Date:10/10/2008)...RICHMOND, Va., Oct. 10 /PRNewswire/ -- Do you thin...Can,t get around town? Attend the October,17 open ...e Blind and,Vision Impaired, and see how instructo...o lead productive, fulfilling lives through non-vi..., located at 401 Azalea Avenue, is holding an open...
(Date:10/10/2008)... Upon the completion of a hig...vision of CDM Media proudly announces their next b...ief information technology executives in healthcar...it will launch May 10-12, 2009 at the Four Seasons... Honolulu, HI (PRWEB) October 11, 2008 -- Upon ...
Breaking Medicine News(10 mins):Health News:Antibiotics May Not Cause Diarrheal Bacteria 2Health News:Synvista Therapeutics Appoints William Federici to its Board of Directors 2Health News:Synvista Therapeutics Appoints William Federici to its Board of Directors 3Health News:Virginia Rehabilitation Center for the Blind and Vision Impaired Celebrates Opening of New Student Dormitory 2Health News:CIO Healthcare Summit Announces Dates and VIP Delegates 2
...at awards and accomplishments could have a profoun...car winners have been on an average found to live ...t the race and went home and empty-handed. The in...d actresses can be found in the latest issue of th...
...lular biologist who is the principle investigator ...of taste cells would help them to discover molecul...stes.// Researchers from the Monell Chemical Sense...eceptor cells outside the body. They have also bee...
...ly harms the teeth by way of discoloring them, it ...nal treatment, according to a new study // appeari...earch. "The findings substantiate what most of u...o your health," Elizabeth Krall Kaye, PhD, MPH, ep...
...PhD, with the Bradley Hasbro Children's Research C... effect of asthma on children. She said that // th...ving skills may be less likely to have their asthm...inspite of facing the stress related to urban scen...
Other Medicine News:Health News:Oscar Winners Live Longer Than Co-Competitors 2Health News:Functional Taste Cells Cultured In Vitro 2
...mory capabilities for overnight sleep screening.,...turation and pulse rate data, and can operate in t...,1. The Model 130 can retain up to 30 minutes of...ce ideally suited for treadmill or other long-dura...
...d Pulse Oximeter provides SpO 2 and pulse rate mo...evice is battery or AC powered, has adjustable ala...gnals, and an infrared link to a printer (catalog ...for added protection. The digital technology util...
The FingerPrint Pulse Oximeter is a low cost Hand-Held Pulse Oximeter with an integral printer. A light-weight, highly portable device providing SpO 2 and pulse rate measurements, it has easy-to-re
...oring system compatible with personal computers or...d and cost-effective.The BCI 3301 HAND-HELD PULSE ...try wherever spot-checking is needed... including ...spitals. In fact, its ergonomic design, easy-to-re...
Medicine Products: